皮肤T细胞淋巴瘤的免疫治疗进展

摘要/Abstract

摘要： 皮肤T细胞淋巴瘤(cutaneous Tcell lymphoma,CTCL)是一组异质性的T细胞来源的恶性肿瘤,以皮肤损害为初发和突出表现。近年来,其发生率和病死率呈上升趋势,严重威胁人类的健康。早期CTCL治疗效果一般较好,但对中晚期CTCL目前尚无有效的治疗方法。随着对抗肿瘤免疫机制的深入了解和CTCL生物学特性的深入研究,免疫治疗已逐渐成为CTCL临床上重要而有效的辅助治疗手段。

徐秀莲, 孙建方. 皮肤T细胞淋巴瘤的免疫治疗进展[J]. 中华皮肤科杂志, 2005, 38(10): 654-657.doi:

参考文献

[1] Suchin KR, Cassin M, Gottleib SL, et al. Increased interleukin 5 production in eosinophilic Sezary syndrome:regulation by interferon alfa and interleukin 12. J Am Acad Dermatol, 2001, 44:28-32.
[2] Tsimberidou AM, Giles F, Romaguera J,et al. Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies. Cancer,2004, 100:574-580.
[3] McGinnis KS, Junkins-Hopkins JM, Crawford G, et al. Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma:clinical synergism and possible immunologic mechanisms. J Am Acad Dermatol, 2004, 50:375-379.
[4] Kozlowski A, Charles SA, Harris JM. Development of pegylated interferons for the treatment of chronic hepatitis C. BioDrugs,2001, 15:419-429.
[5] Wysocka M, Zaki MH, French LE, et al.Sezary syndrome patients demonstrate a defect in dendritic cell populations:effects of CD40 ligand and treatment with GM-CSF on dendritic cell numbers and the production of cytokines. Blood, 2002, 100:3287-3294.
[6] Rook AH, Wood GS, Yoo EK, et al. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood,1999, 94:902-908.
[7] Rook AH, Zaki MH, Wysocka M, et al. The role for interleukin-12 therapy of cutaneous T cell lymphoma. Ann N Y Acad Sci, 2001,941:177-184.
[8] Marolleau JP, Baccard M, Flageul B, et al.High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma. Arch Dermatol, 1995, 131:574-579.
[9] Olsen E, Duvic M, Frankel A, et al. Pivotal phase Ⅲ trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol,2001, 19:376-388.
[10] Buggins AG, Mufti GJ, Salisbury J, et al.Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood, 2002,100:1715-1720.
[11] Lundin J, Hagberg H, Repp R, et al. Phase-2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood,2003, 101:4267-4272.
[12] Gautschi O, Blumenthal N, Streit M, et al.Successful treatment of chemotherapy-refractory Sezary syndrome with alemtuzumab (Campath-1H). Eur J Haematol, 2004, 72:61-63.
[13] Kreitman RJ, Wilson WH, White JD, et al.Phase Ⅰ trial of recombinant immunotoxin anti-Tac (Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol, 2000, 18:1622-1636.
[14] Foss FM, Raubitscheck A, Mulshine JL, et al. Phase Ⅰ study of the pharmacokinetics of a radioimmunoconjugate, 90Y-T101, in patients with CD5-expressing leukemia and lymphoma. Clin Cancer Res, 1998, 4:2691-2700.
[15] Haffner AC, Tassis A, Zepter K, et al. Expression of cancer/testis antigens in cutaneous T cell lymphomas. Int J Cancer,2002, 97:668-670.
[16] Passoni L, Scardino A, Bertazzoli C, et al.ALK as a novel lymphoma-associated tumor antigen:identification of 2 HLA-A2.1-restricted CD8 + T-cell epitopes. Blood, 2002, 99:2100-2106.
[17] Linnemann T, Tumenjargal S, Gellrich S, et al. Mimotopes for tumor-specific T lymphocytes in human cancer determined with combinatorial peptide libraries. Eur J Immunol, 2001, 31:156-165.
[18] Berger CL, Wang N, Christensen I, et al.The immune response to class I-associated tumor-specific cutaneous T-cell lymphoma antigens. J Invest Dermatol, 1996, 107:392-397.
[19] Maier T, Tun-Kyi A, Tassis A, et al. Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells.Blood, 2003, 102:2338-2344.
[20] Gong J, Koido S, Chen D, et al. Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. Blood,2002, 99:2512-2517.
[21] Berger CL, Longley BJ, Imaeda S, et al. Tumor-specific peptides in cutaneous T-cell lymphoma:association with class I major histocompatibility complex and possible derivation from the clonotypic T-cell receptor. Int J Cancer, 1998, 76:304-311.
[22] Thirdborough SM, Radcliffe JN, Friedmann PS, et al. Vaccination with DNA encoding a single-chain TCR fusion protein induces anticlonotypic immunity and protects a gainst T-cell lymphoma. Cancer Res, 2002,62:1757-1760.
[23] Okada CY, Wong CP, Denney DW, et al.TCR vaccines for active immunotherapy of T cell malignancies. J Immunol, 1997, 159:5516-5527.
[24] Edstrom DW, Porwit A, Ros AM. Photodynamic therapy with topical 5-aminolevulinic acid for mycosis fungoides:clinical and histological response. Acta Derm Venereol,2001, 81:184-188.
[25] Coors EA, von den Driesch P. Topical photodynamic therapy for patients with therapy-resistant lesions of cutaneous T-cell lymphoma. J Am Acad Dermatol, 2004, 50:363-367.
[26] Fox FE, Niu Z, Tobia A, et al. Photoactivated hypericin is an anti-proliferative agent that induces a high rate of apoptotic death of normal, transformed, and malignant T lymphocytes:implications for the treatment of cutaneous lymphoproliferative and inflammatory disorders. J Invest Dermatol,1998, 111:327-332.